Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02ZML
|
||||
| Former ID |
DIB019983
|
||||
| Drug Name |
GW-5823
|
||||
| Synonyms |
GW5823; GW 5823
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C35H33N5O4
|
||||
| InChI |
InChI=1S/C35H33N5O4/c1-23(2)39(25-17-19-26(44-3)20-18-25)33(41)22-38-31-15-9-10-16-32(31)40(24-11-5-4-6-12-24)35(43)28(34(38)42)21-30-27-13-7-8-14-29(27)36-37-30/h4-20,23,28H,21-22H2,1-3H3,(H,36,37)
|
||||
| InChIKey |
LGYKPDHARJMLQN-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Cholecystokinin receptor type A | Target Info | Agonist | [2] | |
| Gastrin/cholecystokinin type B receptor | Target Info | Antagonist | [2] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Insulin secretion | |||||
| Pancreatic secretionhsa04020:Calcium signaling pathway | |||||
| Gastric acid secretion | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| PathWhiz Pathway | Gastric Acid Production | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (q) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
| G alpha (q) signalling events | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| Secretion of Hydrochloric Acid in Parietal Cells | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 865). | ||||
| REF 2 | Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J Med Chem. 1997 Aug 15;40(17):2706-25. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.